Evidence map›Paper›PMID 31496734›Full record

ArticleOncoTargets and therapy2019

Silencing of CARMA3 inhibits bladder cancer cell migration and invasion via deactivating β-catenin signaling pathway.

Xiaojun Man, Tao Liu, Yuanjun Jiang, Zhe Zhang, Yuyan Zhu, Zhenhua Li, Chuize Kong, Jiani He

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of the CBM complex in allergic inflammation and disease.The Journal of allergy and clinical immunology · 2022
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaojun ManDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Tao LiuDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Yuanjun JiangDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Zhe ZhangDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Yuyan ZhuDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Zhenhua LiDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Chuize KongDepartment of Urology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Jiani HeBreast Division, Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
First Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder cancer (BC) is the ninth most common cancer and the fourteenth leading death worldwide. CARD-containing MAGUK 3 (CARMA3) protein is a novel scaffold protein known to activate NF-κB pathway and is overexpressed in BC tissues. PURPOSE: The objective of this study was to identify how CARMA3 affects the metastasis of BC cells via the β-catenin signaling pathway. MATERIALS AND

methodsIn the present study, 5637 and T24 BC cells with stable low expression of CARMA3 were established, and their migratory and invasive capabilities were further evaluated by wound-healing and transwell assay. The activity and expression of β-catenin were determined by Luciferase assay and immunofluoresence staining. The mRNA and protein expression levels of CARMA3, matrix metallopeptidase (MMP) 9 and MMP2 were detected by quantitative real-time PCR (qRT-PCR) and Western blot analysis. The nude mouse tumor xenograft model was established for in vivo study.

resultsBy comparison to the control cells, CARMA3-silenced cells acquired a less aggressive phenotype: decreased migration and invasion. More importantly, we confirmed that CARM3 knockdown could inhibit β-catenin mRNA and protein expression and activity, and reduce the expression and/or activity of matrix metallopeptidase (MMP) 9, MMP2 and C-myc. Also, CARM3 silencing increased E-cadherin expression and attenuated the expression of β-catenin. Moreover, we demonstrated that β-catenin overexpression reversed the inhibiting effect of CARMA3 silencing on cell invasion and migration. Furthermore, our study illustrated that knockdown of CARMA3 suppressed BC cells xenograft tumor growth in nude mice.

conclusionWe demonstrated that CARMA3 contributes to the malignant phenotype of BC cells at least by activating β-catenin signaling pathway, and it may serve as a therapeutic target for clinic treatment in BC.

Indexed as

bladder cancerCARMA3invasionmigrationβ-catenin signaling pathway

Identifiers

PMID31496734
PMCPMC6693424
OpenAlexW2967435904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.